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Abstract
Introduction: Adenosquamous carcinoma of the pancreas is a rare variant of exocrine pancreatic
tumor. This type of tumor is extremely rare as only few similar cases have been described in the
literature.
Case presentation: We present a case of a 72 years old male patient who was admitted to the
hospital complaining of epigastric pain and jaundice. Pancreatic carcinoma of the head was
diagnosed and a pylorus preserving pancreaticoduodenectomy was performed.
Conclusion: This type of cancer is a very aggressive tumor followed by a dismisal prognosis.
Multimodality therapy seems to be a reasonable approach but more studies are needed, to propose
the most effective treatment.
Introduction
Pancreatic cancer is the 6th leading cause of death in
Europe, while the incidence rate approaches the mortality
rate [1]. Adenosquamous carcinoma is a rare entity of
pancreatic cancer. Institutional reviews of autopsy and
surgical specimens suggest an incidence of approximately
4% of all pancreatic neoplasms. It has been variously
referred to as adenoacanthoma, mixed squamous and
adenocarcinoma, and mucoepidermoid carcinoma. Only
a few cases, 150 approximately, have been reported in the
accessible literature, until 2008 [2]. Largest series pub-
lished are from Rahemtullah et al and Kardon et al, with
14 and 25 cases respectively [3,4].
Case presentation
A 72-years-old Caucasian Greek male patient presented
with epigastric pain of low intensity, jaundice and loss of
appetite for the past 30 days. The patient was a heavy
smoker (50 cig/day) and consumed alcohol (wine) occa-
sionally, in small quantities. Physical examination
revealed a distressed male patient with a body tempera-
ture of 37°C, blood pressure of 130/85 mmHg and pulse
rate about 85/min. Painless jaundice was the presenting
symptom and Courvoisier sign was present. The patient
had no sings of ascites, or gastrointestinal obstruction.
Hematocrit was 31%, white blood cells 10630/μL with
neutrophil prevalence 77% and platelets 341.000/μL. Bio-
chemical profile showed Tbil: 7.50 mg/dl, Dbil: 5.50 mg/
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dl, SGOT: 109 U/L, SGPT: 145 U/L, γGT: 517 U/L, ALP:
467 U/L, LDH: 503 U/L, CA125: 244, 50 U/L, CA19.9:
51.30 U/L. The patient was receiving digoxin and warfarin
for chronic atrial fibrillation. Thin section computer tom-
ography showed dilatation of the gallbladder and intra/
extrahepatic biliary tree, while a 5 cm mass of the uncinate
process of the pancreas was identified to invade the intra-
pancreatic portion of the bile duct, as well as the 2nd and
3rd portion of the duodenum (Figure 1). There was no
extrapancreatic disease, no extension to the superior
mesenteric artery and celiac axis. The superior mesenteric-
portal confluence was patent. The decision for surgical
intervention was taken, and a pylorus preserving pancrea-
ticoduodenectomy was performed after exploratory lapar-
oscopy. The patient had an uneventful postoperative
course and discharged on the 11th day.
Histological evaluation of the pancreatic tumor showed
an adenosquamous carcinoma which was extensively
infiltrative with perineural invasion, involvement of peri-
pancreatic lymph nodes and all the thickness of the duo-
denum wall. The tumor elicited an intense desmoplastic
stromal reaction and areas of necrosis (Figure 2). Focal
areas of high grade pancreatic intraepithelial neoplasia
were seen. The tumor exhibited a biphasic malignant
growth identified as, well to moderate differentiated ade-
nocarcinoma and well to poorly differentiated squamous
cell carcinoma (Figure 3). The adenocarcinoma compo-
nent contained ductal or glandular structures with focal
intracellular or extracellular mucin (Figure 4). Squamous
differentiation was characterized by irregular and infiltra-
tive nests or sheets of polygonal cells with distinct cellular
borders, intercellular bridges, eosiniphilic cytoplasm and
varying degrees of keratinization (Figure 5). These two dif-
ferent patterns could be seen separated topographically
within the substance of the tumor or intimately admixed.
Six of the 15 resected lymph nodes were positive for met-
astatic tumor which was composed of squamous carci-
noma only (Figure 6).
The immunohistochemical study showed that the tumor
cells were positive for cytokeratin AE1 and AE2. Cam 5.2
and Ker 7 were reactive predominantly in the adenocarci-
noma component and in few squamous cells (Figure 7).
Immunoreactivity for CK 5/6 was restricted to the squa-
mous component, while the glandular component was
negative (Figure 8). A few number of tumor cells were
immunoreactive with CEA and Ca 19-9. All tumor cells
were negative for Ker 20, chromogranin and synapto-
physin.
CT scan of the patient showing the tumor Figure 1
CT scan of the patient showing the tumor.
(H&E ×20) Adenosquamous carcinoma of the pancreas with  area of necrosis Figure 2
(H&E ×20) Adenosquamous carcinoma of the pan-
creas with area of necrosis.
(H&E ×40) Adenosquamous carcinoma of the pancreas Figure 3
(H&E ×40) Adenosquamous carcinoma of the pan-
creas.Cases Journal 2009, 2:9129 http://www.casesjournal.com/content/2/1/9129
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The patient received adjuvant therapy (5-FU in combina-
tion with radiation). He received 40 Gy in two 20 - Gy
courses and 500 mg per m2 5-FU by intravenous bolus
delivered daily for the initial 3 days of each radiation
course and then weekly. The patient 24 months postoper-
atively, remains disease free.
Discussion
The incidence of adenosquamous carcinoma of the pan-
creas ranges among studies from 3% [5] to 11.1% [6],
however the true incidence is not known since this is an
aggressive tumor and most patients have not undergone
surgery or autopsy. A few theories have been reported con-
cerning the formation of adenosquamous carcinoma in
an organ, where almost exclusively adenocarcinoma is the
predominant cancer involved. One such theory postulates
that a metaplastic squamous epithelium undergoes malig-
nant transformation. Additionally, a preexisting adeno-
carcinoma could undergo malignant change and finally, a
primitive cell may be capable of differentiating to either
squamous or adeno component [6].
Preoperative diagnosis is often difficult, as there are no
specific characteristics that can identify the squamous
component in the lesion. However, Ga-67 citrate scintig-
(H&E ×100) Adenocarcinoma similar to ductal carcinoma Figure 4
(H&E ×100) Adenocarcinoma similar to ductal carci-
noma.
(H&E ×200) Squamous cell carcinoma composed of irregular  nests of polygonal cells with no gland formation Figure 5
(H&E ×200) Squamous cell carcinoma composed of 
irregular nests of polygonal cells with no gland for-
mation.
(H&E ×100) Lymph node metastasis only from the squamous  element Figure 6
(H&E ×100) Lymph node metastasis only from the 
squamous element.
(Ker7 ×100) Ker7 showed predilection for adenocarcinoma Figure 7
(Ker7 ×100) Ker7 showed predilection for adenocar-
cinoma.Cases Journal 2009, 2:9129 http://www.casesjournal.com/content/2/1/9129
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raphy may be useful in detecting adenosquamous carci-
noma of the pancreas [7]. On CT imaging, features
suggestive of adenosquamous carcinomas of the pancreas
include large infiltrative lesions and the presence of cen-
tral necrosis [8]. Nabae et al. concluded that the presence
of central necrosis in an infiltrative huge pancreatic tumor
seems to be suggestive of the diagnosis of adenosqua-
mous carcinoma of the pancreas [9]. The role of endo-
scopic US-guided FNA biopsy remains controversial.
Once the diagnosis is established either preoperative or
postoperative, the question that rises refers to the best
treatment modality for this aggressive tumor of the pan-
creas. From the literature reviewed, there is no study with
significant statistical power to address that question.
Smoot et al. demonstrated a longer survival for patients
that can undergo an R0 resection. For R0 resection median
survival was 14.4 months compared to 8 months for R1
and 4.8 months for patients undergoing palliative thera-
pies [10]. Hsu JT et al. showed that the cumulative survival
rates of 12 patients with pancreatic adenosquamous carci-
nomas, ranged from 1.12 to 22.42 months, with a median
of 4.41 months. Additionally, patients with pancreatic
adenosquamous carcinomas had shorter median survival
compared to those with adenocarcinoma 6.51 months vs.
9.76 months [11]. Multidisciplinary treatments including
aggressive surgery, intraoperative radiation therapy, and
locoregional chemotherapy have also been reported to
improve the survival of patients with adenosquamous car-
cinoma of the pancreas and to inhibit liver metastasis and
local recurrence [12]. Shibagaki K et al. presented a case of
successful use of chemoradiotherapy with low-dose cis-
pastin and additional combined chemotherapy with S-1
and cisplatin for unresectable pancreatic adenosquamous
carcinoma [13]. Tanaka N et al. suggested that combined
chemotherapy with cytokines (IFN-a plus TNF-a) and 5-
FU may be a therapeutic modality for advanced pancreatic
cancer [14]. Wilkowski R, et al. concluded that gemcitab-
ine and cisplatin can safely be combined with external
beam radiation. This preoperative treatment approach is
highly effective and appears to improve survival in
patients whose tumors are rendered completely resectable
[15]. However, there have been no sufficient studies that
could propose a treatment modality for this rare tumor.
Conclusion
It has become clear that this type of cancer has a dismissal
prognosis. Even with aggressive therapies median survival
is poor. More studies are needed to address the role of sur-
gery and the use of adjuvant therapy, however this is quite
difficult as this tumor entity is extremely rare. Since squa-
mous cell carcinomas seem to respond satisfactory to
chemoradiotherapy regimens based on 5-FU, this combi-
nation could be potentially used as adjuvant therapy in
patients with resectable squamous cell pancreatic cancer,
or as palliative therapy for unresectable tumors. R0 resec-
tion remains the gold standard for those individuals who
are fit enough to undergo such a major operation.
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